{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:10:09Z","timestamp":1792638609663,"version":"4.5.0"},"reference-count":64,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Graduate Student Fellowship NRSA F30CA23197"],"award-info":[{"award-number":["Graduate Student Fellowship NRSA F30CA23197"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35GM118070"],"award-info":[{"award-number":["R35GM118070"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["T2016-012"],"award-info":[{"award-number":["T2016-012"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["AWD-430131"],"award-info":[{"award-number":["AWD-430131"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7020-19"],"award-info":[{"award-number":["7020-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,10,17]]},"abstract":"<jats:p>While leukemic cells are susceptible to various therapeutic insults, residence in the bone marrow microenvironment typically confers protection from a wide range of drugs. Thus, understanding the unique molecular changes elicited by the marrow is of critical importance toward improving therapeutic outcomes. In this study, we demonstrate that aberrant activation of oxidative phosphorylation serves to induce therapeutic resistance in FLT3 mutant human AML cells challenged with FLT3 inhibitor drugs. Importantly, our findings show that AML cells are protected from apoptosis following FLT3 inhibition due to marrow-mediated activation of ATM, which in turn upregulates oxidative phosphorylation via mTOR signaling. mTOR is required for the bone marrow stroma-dependent maintenance of protein translation, with selective polysome enrichment of oxidative phosphorylation transcripts, despite FLT3 inhibition. To investigate the therapeutic significance of this finding, we tested the mTOR inhibitor everolimus in combination with the FLT3 inhibitor quizartinib in primary human AML xenograft models. While marrow resident AML cells were highly resistant to quizartinib alone, the addition of everolimus induced profound reduction in tumor burden and prevented relapse. Taken together, these data provide a novel mechanistic understanding of marrow-based therapeutic resistance and a promising strategy for improved treatment of FLT3 mutant AML patients.<\/jats:p>","DOI":"10.7554\/elife.79940","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T06:00:10Z","timestamp":1666159210000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.79940","source":"Crossref","is-referenced-by-count":33,"title":["Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation"],"prefix":"10.7554","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-9297","authenticated-orcid":true,"given":"Hae J","family":"Park","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]},{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical Scientist Training Program, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Gregory","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadym","family":"Zaberezhnyy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goodspeed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacology, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]},{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T","family":"Jordan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Section of Hematology, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Kieft","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-1976","authenticated-orcid":true,"given":"James","family":"DeGregori","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]},{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]},{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Section of Hematology, University of Colorado Anschutz Medical Campus","place":["Aurora, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.584232","article-title":"HS-5 and HS-27A stromal cell lines to study bone marrow mesenchymal stromal cell-mediated support to cancer development","volume":"8","author":"Adamo","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1073\/pnas.0913860107","article-title":"Atm signals to TSC2 in the cytoplasm to regulate mtorc1 in response to ROS","volume":"107","author":"Alexander","year":"2010","journal-title":"PNAS"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbamcr.2015.08.003","article-title":"The role of microenvironment and immunity in drug response in leukemia","volume":"1863","author":"Bakker","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.exphem.2018.08.004","article-title":"Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response","volume":"67","author":"Barve","year":"2018","journal-title":"Experimental Hematology"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.molmed.2017.01.005","article-title":"\u201c did He who made the lamb make thee? \u201d new developments in treating the \u201c fearful symmetry \u201d of acute myeloid leukemia","volume":"23","author":"Brumatti","year":"2017","journal-title":"Trends in Molecular Medicine"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"bib8","article-title":"BBTools:bbmap","volume-title":"BBTools:BBMap","author":"Bushnell","year":"2019","unstructured":"Bushnell B. 2019. BBTools:bbmap. BBTools:BBMap. https:\/\/sourceforge.net\/projects\/bbmap."},{"key":"bib9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.molcel.2010.10.030","article-title":"Mtorc1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1\u03b1","volume":"40","author":"Cam","year":"2010","journal-title":"Molecular Cell"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Advances"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clbc.2014.07.002","article-title":"Everolimus-induced hematologic changes in patients with metastatic breast cancer","volume":"15","author":"Chen","year":"2015","journal-title":"Clinical Breast Cancer"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/mc.22239","article-title":"Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K\/akt-p27 (kip1) axis","volume":"54","author":"Chen","year":"2015","journal-title":"Molecular Carcinogenesis"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3727\/096504016X14634208143021","article-title":"Induction of multidrug resistance of acute myeloid leukemia cells by cocultured stromal cells via upregulation of the PI3K\/Akt signaling pathway","volume":"24","author":"Chen","year":"2016","journal-title":"Oncology Research"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41375-019-0458-0","article-title":"Blocking ATM-dependent NF-\u03baB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia","volume":"33","author":"Chen","year":"2019","journal-title":"Leukemia"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2B study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (quantum-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"The Lancet. Oncology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nature06322","article-title":"Mtor controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3324\/haematol.2020.257964","article-title":"Genome-Wide CRISPR screen identifies regulators of MAPK and mTOR pathways mediating sorafenib resistance in acute myeloid leukemia","volume":"107","author":"Damnernsawad","year":"2022","journal-title":"Haematologica"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"Star: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"bib22","article-title":"Msigdbr: msigdb gene sets for multiple organisms in a tidy data format","volume-title":"R Package Version 7.4.1","author":"Dolgalev","year":"2021","unstructured":"Dolgalev I. 2021. Msigdbr: msigdb gene sets for multiple organisms in a tidy data format. R Package Version 7.4.1. https:\/\/CRAN.R-project.org\/package=msigdbr."},{"key":"bib23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/blood-2018-03-838946","article-title":"Csf1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells","volume":"133","author":"Edwards","year":"2019","journal-title":"Blood"},{"key":"bib24","first-page":"175","article-title":"Treatment of FLT3-ITD acute myeloid leukemia","volume":"1","author":"Fathi","year":"2011","journal-title":"American Journal of Blood Research"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/s0301-472x(01)00612-9","article-title":"Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)","volume":"29","author":"Garrido","year":"2001","journal-title":"Experimental Hematology"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1101\/gad.305631.117","article-title":"Hyperactive mTOR and Mnk1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming","volume":"31","author":"Geter","year":"2017","journal-title":"Genes & Development"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"E6669","DOI":"10.1073\/pnas.1603876113","article-title":"ATM\/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia","volume":"113","author":"Gregory","year":"2016","journal-title":"PNAS"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.cellsig.2008.04.011","article-title":"Atm protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells","volume":"20","author":"Halaby","year":"2008","journal-title":"Cellular Signalling"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.stem.2021.02.013","article-title":"Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors","volume":"28","author":"Jones","year":"2021","journal-title":"Stem Cell"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"bib33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf3735","article-title":"Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia","volume":"8","author":"Lam","year":"2016","journal-title":"Science Translational Medicine"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Advances"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ncb3527","article-title":"Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation","volume":"19","author":"Liu","year":"2017","journal-title":"Nature Cell Biology"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"Mtor at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","article-title":"Mtorc1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation","volume":"18","author":"Morita","year":"2013","journal-title":"Cell Metabolism"},{"key":"bib40","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700492","article-title":"Opp labeling enables total protein synthesis quantification in CHO production cell lines at the single-cell level","volume":"13","author":"Nagelreiter","year":"2018","journal-title":"Biotechnology Journal"},{"key":"bib41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33982-y","article-title":"Repression of Mcl-1 expression by the CDC7\/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML","volume":"8","author":"O\u2019 Reilly","year":"2018","journal-title":"Scientific Reports"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1038\/s41375-020-0858-1","article-title":"Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms","volume":"34","author":"Patel","year":"2020","journal-title":"Leukemia"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"The Lancet. Oncology"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory flt3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"bib45","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Research"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"Flt3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"Mtor signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"bib48","doi-asserted-by":"publisher","DOI":"10.1101\/060012","article-title":"An Algorithm for Fast Preranked Gene Set Enrichment Analysis Using Cumulative Statistic Calculation","volume-title":"bioRxiv","author":"Sergushichev","year":"2016"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment-home of the leukemic blasts","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Reviews"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.1128\/MCB.19.9.6076","article-title":"Cleavage and inactivation of ATM during apoptosis","volume":"19","author":"Smith","year":"1999","journal-title":"Molecular and Cellular Biology"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2014-08-594408","article-title":"Aml cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress","volume":"125","author":"Sriskanthadevan","year":"2015","journal-title":"Blood"},{"key":"bib53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3627.3627","article-title":"A phase I trial of escalating dose of the rapamycin analog everolimus in combination with the kinase inhibitor midostaurin in patients (PTS) with relapsed, refractory or poor prognosis acute myeloid leukemia (AML)","volume":"120","author":"Stone","year":"2012","journal-title":"Blood"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","article-title":"Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia","volume":"3","author":"Sung","year":"2019","journal-title":"Blood Advances"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11899-015-0253-6","article-title":"Role of microenvironment in resistance to therapy in AML","volume":"10","author":"Tabe","year":"2015","journal-title":"Current Hematologic Malignancy Reports"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Tamburini","year":"2009","journal-title":"Blood"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1080\/10428194.2017.1413188","article-title":"Dna damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells","volume":"59","author":"Tang","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11083","article-title":"A unifying model for mTORC1-mediated regulation of mRNA translation","volume":"485","author":"Thoreen","year":"2012","journal-title":"Nature"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"Fgf2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Research"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"F1300","DOI":"10.1152\/ajprenal.00509.2005","article-title":"Caspase-Mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53","volume":"291","author":"Wang","year":"2006","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/35046542","article-title":"Participation of ATM in insulin signalling through phosphorylation of eif-4E-binding protein 1","volume":"2","author":"Yang","year":"2000","journal-title":"Nature Cell Biology"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang","year":"2014","journal-title":"British Journal of Haematology"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/JLB.6A0821-409RR","article-title":"Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy","volume":"112","author":"You","year":"2022","journal-title":"Journal of Leukocyte Biology"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","article-title":"Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment","volume":"120","author":"Zeng","year":"2012","journal-title":"Blood"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/79940\/elife-79940-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/79940\/elife-79940-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/79940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:23:18Z","timestamp":1697059398000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/79940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":64,"alternative-id":["10.7554\/eLife.79940"],"URL":"https:\/\/doi.org\/10.7554\/elife.79940","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.14.480468","asserted-by":"subject"}],"references":[{"id-type":"accession","id":"GSE61019","asserted-by":"subject"}],"is-supplemented-by":[{"id-type":"accession","id":"GSE202230","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.79940.sa0","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.79940.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.79940.sa2","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e79940"}}